In the BioHarmony Drug Report Database

"Preview" Icon

Inotersen

Tegsedi (inotersen) is an oligonucleotide pharmaceutical. Inotersen was first approved as Tegsedi on 2018-07-06. It is used to treat familial amyloid neuropathies in the USA. It has been approved in Europe to treat amyloidosis. Tegsedi’s patents are valid until 2031-04-29 (FDA).

 

Trade Name

 

Tegsedi
 

Common Name

 

inotersen
 

ChEMBL ID

 

CHEMBL4297770
 

Indication

 

amyloidosis, familial amyloid neuropathies
 

Drug Class

 

Antisense oligonucleotides

Image (chem structure or protein)

Inotersen structure rendering